Equities

Tissue Regenix Group PLC

TRX:LSE

Tissue Regenix Group PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)61.00
  • Today's Change-0.50 / -0.81%
  • Shares traded55.02k
  • 1 Year change1.67%
  • Beta1.9981
Data delayed at least 20 minutes, as of May 01 2024 16:34 BST.
More ▼

Profile data is unavailable for this security.

About the company

Tissue Regenix Group plc is a medical device company in regenerative medicine. The principal activity of the Company is the exploitation of platform technologies in the field of bone graft substitutes and soft tissue. It is focused on the development of regenerative products utilizing its two platform technologies, dCELL, addressing soft tissue needs, and BioRinse, providing sterile bone allografts. Its divisions include dCELL, BioRinse and GBM-V. The Company's patented decellularization technology (dCELL) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Its proprietary BioRinse technology platform is primarily utilized to provide sterile tissue prepared in a manner to minimize the negative effects of processing. GBM-V produces tissue preparations for ophthalmology, primarily cornea, using conventional, classical methods.

  • Revenue in GBP (TTM)23.61m
  • Net income in GBP-1.37m
  • Incorporated2006
  • Employees76.00
  • Location
    Tissue Regenix Group PLCUnit 3Phoenix Court, Lotherton Way, GarforthLEEDS LS25 2GYUnited KingdomGBR
  • Phone+44 19 0456 7609Fax+44 19 0438 0517
  • Websitehttps://www.tissueregenix.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Checkit PLC12.00m-4.50m23.76m163.0023.76m163.00
Tinybuild Inc35.76m-50.07m28.35m400.0028.35m400.00
Fadel Partners Inc9.50m-3.00m28.99m116.0028.99m116.00
Tpximpact Holdings PLC77.22m-24.07m29.49m735.0029.49m735.00
Renalytix PLC2.72m-37.01m33.38m80.0033.38m80.00
GetBusy PLC21.11m-227.00k33.63m146.0033.63m146.00
Zoo Digital Group plc48.24m-4.30m37.89m558.0037.89m558.00
Tissue Regenix Group PLC23.61m-1.37m43.65m76.0043.65m76.00
PCI- PAL PLC16.42m-3.76m44.65m114.0044.65m114.00
Aurrigo International PLC6.11m-3.86m45.16m58.0045.16m58.00
K3 Business Technology Group plc43.78m-2.39m46.30m322.0046.30m322.00
Cirata PLC5.36m-29.21m50.15m112.0050.15m112.00
RM plc195.19m-43.31m60.60m1.83k60.60m1.83k
Corero Network Security PLC17.89m-136.11k61.41m76.0061.41m76.00
Intercede Group plc13.04m1.65m61.43m91.0061.43m91.00
Data as of May 01 2024. Currency figures normalised to Tissue Regenix Group PLC's reporting currency: UK Pound GBX

Institutional shareholders

49.33%Per cent of shares held by top holders
HolderShares% Held
Harwood Capital LLPas of 29 Feb 202410.62m15.04%
Lombard Odier Asset Management (Europe) Ltd.as of 04 Apr 20247.78m11.03%
Hargreaves Lansdown Asset Management Ltd.as of 01 Apr 20246.12m8.67%
UBS Asset Management (UK) Ltd.as of 01 Apr 20244.08m5.78%
Janus Henderson Investors UK Ltd.as of 01 Apr 20243.58m5.07%
IG Markets Ltd.as of 01 Apr 20241.04m1.48%
Close Asset Management Ltd.as of 01 Apr 2024475.00k0.67%
HSBC Global Asset Management (UK) Ltd.as of 01 Apr 2024429.00k0.61%
J. M. Finn & Co. Ltd.as of 01 Apr 2024397.00k0.56%
KBC Asset Management NVas of 01 Apr 2024301.00k0.43%
More ▼
Data from 31 Jan 2023 - 02 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.